Comparison of Alternative Lipid Emulsions on Morbidities in Very-Low-Birth-Weight Preterms

Abstract

To compare clinical outcomes of using different alternative lipid emulsions for longer durations in babies who are at high risk for preterm morbidities. Preterm infants born ≤30 wk receiving SMOFlipid versus Clinoleic with longer durations (≥ 14 d) wereincluded in this retrospective study. The authors compared demographic features, clinical applications, and morbidities between epochs: epoch 1 (Clinoleic, July 2017-June 2018) versus epoch 2 (SMOFlipid, July 2018-June 2019). A total of 91 infants were included in the study. In bivariate analysis; moderate bronchopulmonary dysplasia(BPD) (p = 0.000) and composite outcome [BPD, retinopathy of prematurity (ROP) needed treatment, cholestasis and late-onset sepsis and/or mortality] rates were significantly higher (p = 0.043) in Clinoleic group. In multivariate logistic regression analysis, it was found that the type of lipid emulsion used had no significant effect on these morbidities. Since both groups had comparable morbidity and mortality, both lipid emulsions are equally safe in preterm babies requiring parenteral nutrition.